secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2025-09-03T23:59:59+00:00
Accession:  0000950170-25-112674
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene achieves target enrollment of 100 patients in Phase 2 LEGEND trial for detalimogene in BCG-unresponsive NMIBC
--------------------------------------------------------------------------------

- Target enrollment of 100 patients reached in Cohort 1 of Phase 2 LEGEND trial.
- Trial evaluates detalimogene voraplasmid in high-risk, BCG-unresponsive NMIBC with CIS ± papillary disease.
- Corporate presentation updated September 3, 2025; news release issued same day.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000095017025112674/0000950170-25-112674-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000095017025112674/engn-20250903.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-112674

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer